Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Ovarian Neoplasms 2Neoplasms 2Lung Neoplasms 2Advanced Solid Tumours 2Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Neoplasms by Site 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lung Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hereditary Sensory and Autonomic Neuropathies 1Endometrial Neoplasms 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1Advanced Solid Malignancies 1

Interventions

Paclitaxel 113Carboplatin 99Bevacizumab 59pembrolizumab 56liposomal doxorubicin 56Gemcitabine 42olaparib 39Topotecan 33niraparib 29Nivolumab 21Cisplatin 21Doxorubicin 17Cyclophosphamide 171-dodecylpyridoxal 16Drug Therapy 15Docetaxel 15avelumab 13Fulvestrant 11oregovomab 10Oxaliplatin 10rucaparib 9fludarabine 9Injections 9Fluorouracil 9veliparib 8mirvetuximab soravtansine 8atezolizumab 8Cetuximab 8fluzoparib 7cemiplimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Neoplasms × ceralasertib × Clear all
NCT06754761 2025-01-01

Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib

AstraZeneca

Phase 1 Not yet recruiting
8 enrolled
GynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT04239014 2021-03-10

DUETTE

AstraZeneca

Phase 2 Withdrawn
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡